Convalescent Blood Products in COVID-19: A NarrativeReview

摘要

The coronavirus disease 2019 (COVID-19) pandemic has left the world in a state ofdesolation with overburdening public health systems in a short period. Findingpossible preventative and therapeutic measures to counter severe respiratorysyndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has beenthe priority. A possible solution is convalescent blood products (CBP),primarily convalescent plasma (CP) and immunoglobulins, as an adjunctivetherapy. CBP has been tried on the previous coronavirus epidemics with severeacute respiratory syndrome coronavirus (SARS-CoV) and the Middle EastRespiratory Syndrome Coronavirus (MERS-CoV). Therefore, we reviewed the clinicalutility of CBP and available evidence in COVID-19. We found some of the currentanecdotal studies demonstrate promising therapeutic potential, but many of thesestudies do not meet the academic rigours to substantiate its use withconfidence. However, the compassionate use of CBP in critically ill COVID-19patients can be an option while we await a definitive answer from ongoingrandomised clinical trials.